Table 1.

Pediatric patients with GSD1b recruited for the EMPAtia/Fixnet observational substudy

SexAge (y)SLC374A mutation NM_001164278.1Protein mutation NP_001157750G-CSF (μg/kg per day)Empagliflozin (mg/kg per day)Antibiotics requiring infections
03 mo12 mo03 mo12 mo1 y before1 y after
P1 17 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.45 0.45 0.44 
P2 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 5.4 2.5 2.5 0.3 0.3 0.27 
P3 11 c.[898C>T];[1042_1043del] p.[(Arg300Cys)];[(p.Leu370Valfs)] 0.47 0.47 0.46 
P4 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.44 0.44 0.42 
P5 14 c.[1015G>T];[1042_1043del] p.[(Gly361Cys)];[(p.Leu370Valfs)] 0.43 0.42 0.4 
P6 19 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.3 0.3 0.27 
P7 c.[1015G>T];[1042_1043del] p.[(Gly361Cys)];[(p.Leu370Valfs)] 0.3 0.3 0.27 
SexAge (y)SLC374A mutation NM_001164278.1Protein mutation NP_001157750G-CSF (μg/kg per day)Empagliflozin (mg/kg per day)Antibiotics requiring infections
03 mo12 mo03 mo12 mo1 y before1 y after
P1 17 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.45 0.45 0.44 
P2 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 5.4 2.5 2.5 0.3 0.3 0.27 
P3 11 c.[898C>T];[1042_1043del] p.[(Arg300Cys)];[(p.Leu370Valfs)] 0.47 0.47 0.46 
P4 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.44 0.44 0.42 
P5 14 c.[1015G>T];[1042_1043del] p.[(Gly361Cys)];[(p.Leu370Valfs)] 0.43 0.42 0.4 
P6 19 c.[1042_1043del];[1042_1043del] p.[(Leu370Valfs)];[(p.Leu370Valfs)] 0.3 0.3 0.27 
P7 c.[1015G>T];[1042_1043del] p.[(Gly361Cys)];[(p.Leu370Valfs)] 0.3 0.3 0.27 

F, female; M, male.

Close Modal

or Create an Account

Close Modal
Close Modal